Professional
Added to YB: 2024-08-20
Pitch date: 2024-07-20
LLY [bullish]
Eli Lilly and Company
+24.12%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$920.0B
Pitch Price
$855.78
Price Target
N/A
Dividend
0.67%
EV/EBITDA
32.91
P/E
50.26
EV/Sales
16.03
Sector
Pharmaceuticals
Category
growth
Show full summary:
Invesco Global Focus Fund New Position: Eli Lilly and Company
LLY: Blockbuster potential in weight loss & diabetes treatments. Supply constraints & limited competition to benefit Lilly & Novo Nordisk for years. Complementary to fund's Novo Nordisk holding.
Read full article (1 min)